Sugi Predict

Sugi Predict / Compounds / Indigotindisulfonate

Indigotindisulfonate

Indigotindisulfonate

SCHEMBL186296

O=C1/C(=C2\Nc3ccc(S(=O)(=O)O)cc3C2=O)Nc2ccc(S(=O)(=O)O)cc21.[NaH].[NaH]

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ CASP3 P42574 7/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ CASP9 P55211 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ THRB P10828 2/20 0.37
▸ BLM P54132 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TGM2 P21980 3/20 0.37
▸ CES1 P23141 3/20 0.37
▸ F2 P00734 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indigotindisulfonate SCHEMBL3652418 1.00 CA12 (0.49) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL3680504 1.00 CA12 (0.49) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL3960977 0.98 CA12 (0.47) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL2732840 0.98 CA12 (0.50) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL5455215 0.98 CA12 (0.50) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL29387846 0.98 CA12 (0.50) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL186297 0.98 CA12 (0.50) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL2727226 0.98 CA12 (0.50) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL9107944 0.96 CA12 (0.49) CA12CA1CA2CA9CASP3
Indigotindisulfonate SCHEMBL29694234 0.96 CA12 (0.49) CA12CA1CA2CA9CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2930126-B1 Fashionable aerosol dye HENKEL AG & CO KGAA (DE) 2019-10-09 — — EP claimed
EP-2303343-B1 METHOD OF PREPARING ADHESIVE COMPOSITIONS FOR MEDICAL USE: SINGLE ADDITIVE AS BOTH THE THICKENING AGENT AND THE ACCELERATOR ADHEZION BIOMEDICAL LLC (US) 2016-01-13 — — EP disclosed
US-9173829-B2 Compositions for dyeing keratin fibers HENKEL AG & CO. KGAA (DE) 2015-11-03 — — US disclosed
US-9161898-B2 Compositions for colouring keratin fibres HENKEL AG & CO. KGAA (DE) 2015-10-20 — — US disclosed
EP-2679251-B1 Adhesive compositions for medical use: single additive as both the thickening agent and the accelerator ADHEZION BIOMEDICAL LLC (US) 2015-08-19 — — EP disclosed
US-20140298592-A1 COMPOSITIONS FOR DYEING KERATIN FIBERS HENKEL AG & CO. KGAA (DE) 2014-10-09 — — US disclosed
US-20140290690-A1 COMPOSITIONS FOR COLOURING KERATIN FIBRES HENKEL AG & CO. KGAA (DE) 2014-10-02 — — US disclosed
EP-0886507-B2 MONOMERIC COMPOSITIONS EFFECTIVE AS WOUND CLOSURE DEVICES ETHICON INC (US) 2013-03-06 — — EP disclosed
EP-2103299-B1 Oxidizing hair colourant compositions PROCTER & GAMBLE (US) 2013-02-27 — — EP disclosed
US-8153743-B2 Controlled exotherm of cyanoacrylate formulations CLOSURE MEDICAL CORPORATION (US) 2012-04-10 — — US disclosed
WO-1999010020-A1 METHODS OF APPLYING MONOMERIC COMPOSITIONS EFFECTIVE AS WOUND CLOSURE DEVICES CLOSURE MEDICAL CORPORATION (US) 1999-03-04 — — WO disclosed
EP-0886507-A1 MONOMERIC COMPOSITIONS EFFECTIVE AS WOUND CLOSURE DEVICES Closure Medical Corporation (US) 1998-12-30 — — EP disclosed
EP-0767819-A4 pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS TRI POINT MEDICAL CORP (US) 1997-09-24 — — EP disclosed
WO-1997031598-A1 MONOMERIC COMPOSITIONS EFFECTIVE AS WOUND CLOSURE DEVICES CLOSURE MEDICAL CORPORATION (US) 1997-09-04 — — WO disclosed
US-5624669-A APPLYING A BIOCOMPATIBLE ADHESIVE COMPOSITION CONTAINING A FORMALDEHYDE SCAVENGER TRI-POINT MEDICAL CORPORATION (US) 1997-04-29 — — US disclosed
EP-0767819-A1 pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS TRI-POINT MEDICAL CORPORATION (US) 1997-04-16 — — EP disclosed
US-5582834-A APPLYING AN IN VIVO POLYMERIZABLE TISSUE ADHESIVE COMPRISING A FORMALDEHYDE SCAVENGER TRI-POINT MEDICAL, CORPORATION (US) 1996-12-10 — — US disclosed
US-5575997-A CYANTOACRYLATES TRI-POINT MEDICAL CORPORATION (US) 1996-11-19 — — US disclosed
US-5514371-A CYANOACRYLATES TRI-POINT MEDICAL L.P. (US) 1996-05-07 — — US disclosed
WO-1996000760-A1 pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS TRI-POINT MEDICAL CORPORATION (US) 1996-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140290690-A1 COMPOSITIONS FOR COLOURING KERATIN FIBRES KRT18, DSG1, PKN1 CA12 984/4885CA1 3359/4885CA2 3072/4885
US-20140298592-A1 COMPOSITIONS FOR DYEING KERATIN FIBERS KRT18, PKN3, IK CA12 947/4885CA1 2037/4885CA2 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.